Action NOVUS THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Novus Therapeutics, Inc. Nasdaq

Actions

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell 3000E Index
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell Microcap Index
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell Microcap Value Index
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) added to Russell 3000E Value Index
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
Eledon Pharmaceuticals, Inc. announced that it has received $49.99901 million in funding
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
Eledon Pharmaceuticals, Inc. Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
Eledon Pharmaceuticals Says 12th Participant Enrolled in Tegoprubart Trial; Shares Rise After Hours
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ELDN
  4. Action
  5. Actualités Novus Therapeutics, Inc.
  6. Autres langues